Endobetix
Minimally Invasive Solution for Type 2 Diabetes and Obesity
Company Overview
Snapshot
Founded in August 2012 by Chen Porat, Endobetix operates with 1–10 employees. The company has raised $650,000 across one funding round from one investor. In July 2015, Endobetix was awarded a U.S. patent, marking a significant intellectual property milestone.
Business overview
Endobetix is a Health Tech & Life Sciences company focused on developing a minimally invasive, nonsurgical implant for the treatment of Type 2 Diabetes and obesity. Its core product, the Endobetix Bile Diversion Device (BDD), is designed to be implanted endoscopically to reroute bile and pancreatic secretions, thereby altering hormonal balance to improve glucose tolerance and reduce fat absorption. The company operates within the medical devices sector, targeting healthcare providers and hospitals with its gastroenterology-focused solution.
Strategic signal
In July 2015, Endobetix secured a U.S. patent for its technology. This intellectual property milestone is crucial for a medical device company, as it provides a competitive advantage and validates the innovative nature of its minimally invasive solution for Type 2 Diabetes and obesity. For investors, this signals a strengthened market position and potential for future commercialization.
Company Intelligence Q&A
- What is Endobetix's primary focus?
- Endobetix is developing a minimally invasive, nonsurgical implant designed to mimic the hormonal benefits of bariatric surgery for treating Type 2 Diabetes and obesity.
- When was Endobetix founded?
- Endobetix was founded in August 2012.
- Has Endobetix secured any patents?
- Yes, in July 2015, Endobetix was awarded a U.S. patent for its technology.
- What was a notable recognition Endobetix received?
- In April 2015, Endobetix was a finalist for the 2015 Red Herring Top 100 Europe Award.
- What is the Endobetix Bile Diversion Device (BDD)?
- The BDD is an endoscopically implanted device that reroutes bile and pancreatic secretions to change hormonal balance, improving glucose tolerance and reducing fat absorption for Type 2 Diabetes and obesity patients.